Market Size (2018)
$6.21B
Vertical: HealthcareBase Year: 2018
Market Size (2018)
$6.21B
Projected (2025)
$8.56B
CAGR (2016–2025)
4.7%
Key Players
8+
Nephrectomy is a surgical procedure performed to remove the kidney or a part of it. Nephrectomy is of two types, namely, radical nephrectomy in which the entire kidney is removed and partial nephrectomy where a part of the kidney or the diseased tissues is removed as a process of the treatment. Most frequently, a nephrectomy is done to treat kidney cancer or to remove a noncancerous tumor during the urological surgery.
The increase in the prevalence of kidney cancer, kidney diseases and injury to the kidney, rising number of laparoscopic nephrectomy procedures, and growing awareness about organ (kidney) transplant are expected to drive the market growth during the forecast period. However, risks and complications associated with nephrectomy surgery and high cost related to the procedure are anticipated to restrain the market growth.
The Nephrectomy Market market is projected to grow at a CAGR of 4.7% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansNephrectomy is referred to as the surgical procedure for the removal of the kidney. It is performed as a part of the treatment of the diseased kidney. The nephrectomy based on severity of the disease has been classified into partial and radical nephrectomy procedures. In the partial nephrectomy procedure, the injured or diseased section of the kidney is removed, whereas radical nephrectomy comprises removal of the entire kidney.
Various surgical procedures and technologies are adopted depending on the type of nephrectomy. The procedures comprise laparoscopic surgery, robot-assisted laparoscopic surgery, and others.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global nephrectomy market is characterized by the presence of global, regional, and local vendors. The market is highly competitive with all players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional, and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share. Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.
Michael Porter’s five forces model gives a framework that models the global nephrectomy market, which is influenced by five forces. The strategic business managers, trying to create an edge over competing firms in the global nephrectomy market can utilize this model to comprehend better the industry connection in which the firm operates. The components of each of the forces and the degree or impact of each component in the context of the global nephrectomy industry have been broken down and analyzed below.
Bargaining Power of Suppliers
The bargaining power of suppliers in the nephrectomy market is moderate. In this market, the suppliers are medical device manufacturers, laboratory instrument manufacturers, and consumable & accessories manufacturers. There are many major and small companies involved in this market. The bargaining power of suppliers depends on the number of buyers and number of suppliers. In global nephrectomy market the number of buyers is equal to the number of suppliers, and the high cost of switching from one supplier to another increases the bargaining power of suppliers. But, the grey market in medical device industry affects the bargaining power of suppliers. Conclusively the bargaining power of suppliers in the nephrectomy market is m moderate.
Bargaining Power of Buyers
The bargaining power of buyers is moderate to low in the global nephrectomy market. The market has a moderate number of buyers, including clinics, hospitals, surgical centers, and others. The presence of buyers in the market is rising due to the increasing prevalence of kidney cancer, chronic kidney diseases, and other healthcare problem. In addition, the pricing factor also plays an important role in the bargaining power of buyer in the market. The market is characterized by moderate availabilities of substitute products, which holds the buying power at moderate to low.
Threat of New Entrants
The threat of new entrants is moderate to low in the global nephrectomy market. Many medical device manufacturing companies are trying to enter in this market, but the low economies of scale, stringency of government regulations for medical device development and large capital required for the product development hinders the entry of new potential players. But the increasing government support for the healthcare industry supports the new players to enter this market.
Threat of Substitutes
The threat of substitutes in the global nephrectomy market is low. Any threat from a close substitute product is measured to have a high impact on the market. The threat from the substitutes arises when the buyers or the customers in the market can accomplish the end-result using other similar product. Although there is a low number of substitutes or the presence of an alternative line of treatment in the market.
Intensity of Rivalry
The degree of competition in the global nephrectomy market is moderate to high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in the nephrectomy market are trying to develop cost-effective products to make product differentiation more affordable. To overcome the competition, players are engaged in developing a process to lower their manufacturing cost. Moreover, the players are also developing advanced techniques for differentiating their product from their rivals.
Market estimates by geography (2025)
InsightAmericas leads with $2.35B by 2025, while Asia Pacific is projected to grow fastest at a 5.2% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $1.26B | $1.58B | $1.90B | 4.7% | 22% |
| Americas | $1.60B | $1.98B | $2.35B | 4.4% | 27% |
| Asia Pacific | $820.50M | $1.06B | $1.30B | 5.2% | 15% |
| Europe | $1.41B | $1.79B | $2.18B | 5.0% | 26% |
| South America | $343.80M | $402.50M | $454.90M | 3.2% | 5% |
| Rest of the World | $244.70M | $310.90M | $376.50M | 4.9% | 4% |
| Total | $5.67B | $7.13B | $8.56B | 4.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$8.56B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Laparoscopic Nephrectomy | $5.84B | 4.8% | 68% |
| Robot-Assisted Laparoscopic Nephrectomy | $2.32B | 5.1% | 27% |
| Open Nephrectomy | $393.89M | 1.2% | 5% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Nephrectomy Market covering market dynamics, competitive landscape, and strategic outlook.
The Nephrectomy Market market is projected to reach $8.56B by 2025, growing at 4.7% CAGR. The Laparoscopic Nephrectomy segment holds the largest share.
Nephrectomy is a surgical procedure performed to remove the kidney or a part of it. Nephrectomy is of two types, namely, radical nephrectomy and partial nephrectomy. In a radical nephrectomy, the entire kidney is removed along with some additional structures such as tubes connected to kidney and bladder, lymph nodes, and other parts, whereas in partial nephrectomy (kidney-sparing) only the diseased tissues are removed from the kidney.
Nephrectomy is done to treat kidney diseases, kidney cancer, as well as injuries related to the kidney. The procedure is also done to remove a healthy kidney from a donor for transplantation.
The major key factors driving the market growth are increasing prevalence of kidney cancer, chronic kidney diseases, and injury, rising number of laparoscopic procedures and increasing awareness about organ (kidney) donation cross the globe.
However, factors such as risks and complications of the nephrectomy surgery and high cost related to the procedure hamper the market growth.
Along with various treatment applications, the nephrectomy surgery also leads to cause some risk and complications in the person’s body. The post-operative or surgical complication may depend on patients and their medical conditions. The abdominal pain is common after surgery, but if not cured even after medication, it could cause serious problems to the patient’s health. The postoperative complications after the nephrectomy surgery include infection, bleeding (hemorrhage) requiring blood transfusion, post-operative pneumonia, rare allergic reactions to anesthesia, and sometimes death of the patient. In some cases, the nephrectomy surgery may also cause tissue or organ injury, to surrounding tissues and organs including bowel, spleen, vascular structures, liver, gallbladder, and pancreas which may require further surgery to overcome the problem. Such types of issues and risks associated with the nephrectomy surgery may hinder market growth.
Pricing is one of the important factors for any product or service to withstand in the market. Pricing is fixed by considering different parameters such as the cost of the raw material used, technological cost, labor charges, and many more. In the global nephrectomy market, the pricing is considered on the basis of number of procedures, type of procedure performed, and also the technology used to perform the procedure.
Nephrectomy is performed using laparoscopy, robot-assisted laparoscopic surgery, and open surgery methods. The use of robotic surgery has increased in urological (urinary-tract system) operations over the last decade. According to the secondary data it is found that the costs of hospitals are significantly higher for robotic-assisted surgery than laparoscopic radical nephrectomy (RN) (USD 19,530 and USD16,851, respectively), which included higher operating room costs (USD 7217 and USD 5378, respectively) and higher supply costs (USD 4876 and USD 3891, respectively) for the year 2003 to 2015.
Also, according to the study published in 2013 by the National Center for Biotechnology Information, it was reported that open partial nephrectomy (OPN) accounts for the least cost, i.e., USD 25,941 compared to other methods. Whereas laparoscopic radical nephrectomy (LRN) accounts USD 66,935, and laparoscopic partial nephrectomy, (LPN) charges USD 26,829. However, irrespective of the high cost of procedure there is an increase in the demand for these procedures due to the increasing prevalence of kidney disease year on year.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Nephrectomy Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Company Headquarters: Japan Founded: 1919 Workforce: 46,500 Company Working: Olympus Corporation is a Japanese multinational corporation that specializes in manufacturing and selling optical and reprography products, as well as medical and surgical equipment. The company was founded in 1919 and is headquartered in Tokyo, Japan. Olympus Corporation is organized into four main business segments: Medical, Scientific Solutions, Imaging, and Financial. The Medical segment is the largest and most important business segment of the company, accounting for approximately two-thirds of the company's total revenue. The Medical segment includes endoscopy and surgical products, as well as clinical and research microscopes which includes Biopsy devices. Within the Medical segment, Olympus Corporation offers a range of products for minimally invasive surgical procedures, including endoscopes and endotherapy devices. One of the key products offered by Olympus Corporation is its biopsy device, which is used to collect tissue samples from various parts of the body for diagnostic purposes. Olympus Corporation's biopsy device is designed to be used with endoscopes and comes in a range of sizes and shapes to suit different clinical needs. The company has a global presence with operations in various regions around the world. The company's headquarters is located in Tokyo, Japan, and it has several subsidiaries and offices in different countries.
XCELLANCE Medical Technologies (XCELLANCE) is a privately held company that operates in the medical devices industry through its high-end medical equipment. The company offers a variety of products and services. The company has a strong and satisfied customers base owing to the quality and efficiency of its products. It offers products and services to about 3000 hospitals across India.
KARL STORZ SE & Co. KG is the leading manufacturer of endoscopes. The company offers various endoscopic instruments for human and veterinary medical examination as well as for industrial applications. The company has a worldwide presence to support and consult its customers, it has more than 50 subsidiary stores in over 40 countries such as the US, Cuba, Belgium, China, and others.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)